Updates are available Correction dated 2023-10-26

Article History

Accepted: 20 July 2023

First Online: 4 September 2023

Change Date: 26 October 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41584-023-01049-6

Competing interests

: T.T. has received grants and research support from Celsius Therapeutics, and consulting fees from AbbVie and ZuraBio, and has been an employee of Janssen. H.H.U. has received research support and/or consultancy fees from BMS, Eli Lilly, Janssen, Mestag, OMass and UCB Pharma. S.P.L.T. has received grants and/or research support from AbbVie, Buhlmann, Celgene, Celsius Therapeutics, ECCO, Helmsley Trust, IOIBD, Janssen, Lilly, Pfizer, Takeda, UCB, UKIERI, Vifor and the Norman Collisson Foundation, and consulting fees from Abacus, AbbVie, Actial, ai4gi, Alcimed, Allergan, Amgen, Apexian, Aptel, Arena, Asahi, Aspen, Astellas, Atlantic, AstraZeneca, Bioclinica, Biogen, Boehringer Ingelheim, BMS, Buhlmann, Calcico, Celgene, Cellerix, Cerimon, ChemoCentryx, CisBio, Clario, Coronado, Cosmo, Dynavax, Enterome, EQrX, Equillium, Falk, Ferring, Galapagos, Genentech/Roche, Genzyme, Gilead, GSK, Immunocore, Immunometabolism, Janssen, Lilly, Medarex, Merck, Mestag, Neovacs, Novartis, Novo Nordisk, Otsuka, Pentax, Pfizer, Phesi, Phillips, Protagonist, Proximagen, Resolute, Sandoz, Sanofi, Satisfai, Sorriso, Syndermix, Synthon, Takeda, Theravance, Tigenix, Tillotts, Topivert, TxCell, UCB Pharma, Vertex, VHsquared, Vifor, Warner Chilcott and Zeria, and speaker fees from AbbVie, Amgen, Biogen, BMS, Falk, Ferring, Janssen, Lilly, Pfizer, Shire, Takeda and UCB. No stocks or shares. C.D.B. has received research support and/or consultancy fees from Janssen, GSK, BMS, Celsius, Novartis and Roche, and has stocks or share options for Mestag. T.H. and R.R. declare no competing interests.